HISTOGEN INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.35 USD | 0.00% |
|
-30.00% | +13.75% |
| Apr. 18 | Histogen Inc. Filed for Bankruptcy | CI |
| 2023 | Histogen Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Financials (USD)
| Sales 2021 | 1.03M | Sales 2022 | 3.77M | Capitalization | 3.55M |
|---|---|---|---|---|---|
| Net income 2021 | -15M | Net income 2022 | -10M | EV / Sales 2021 | 2.62 x |
| Net cash position 2021 | 13.92M | Net cash position 2022 | 7.48M | EV / Sales 2022 | -1.04 x |
| P/E ratio 2021 |
-0.85
x | P/E ratio 2022 |
-0.24
x | Employees | 7 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.15% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 week | -30.00% | ||
| Current month | -2.80% | ||
| 1 month | -10.26% | ||
| 3 months | +3.86% | ||
| 6 months | +8.36% | ||
| Current year | +13.75% |
1 week
0.05
0.50
1 month
0.050.55
Current year
0.050.55
1 year
0.051.05
3 years
0.0524.60
5 years
0.05105.24
10 years
0.05105.24
| Managers | Title | Age | Since |
|---|---|---|---|
Susan Knudson
CEO | Chief Executive Officer | 60 | 20-05-26 |
Mark A. Hubka
CTO | Chief Tech/Sci/R&D Officer | - | - |
Thomas L. Hubka
PRN | Corporate Officer/Principal | 37 | 20-05-25 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dan Kisner
CHM | Chairman | 77 | 14-01-31 |
| Director/Board Member | 54 | 21-03-24 | |
David Crean
BRD | Director/Board Member | 59 | 20-05-25 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 0.35 | 0.00% | 5 352 |
| 24-04-22 | 0.35 | +133.18% | 55,183 |
| 24-04-19 | 0.1501 | -69.98% | 955 |
| 24-04-18 | 0.5 | 0.00% | 525 |
| 24-04-16 | 0.5 | 0.00% | 1,413 |
Delayed Quote OTC Markets, April 23, 2024 at 03:45 pm EDT
More quotes
Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the bodyâs natural process to restore immune function. Its product candidates include emricasan, CTS-2090 and CTS-2096. It develops emricasan for acute bacterial skin and skin structure infections (ABSSSI) as well evaluating its use for other infectious diseases. Its pipeline also includes novel preclinical product candidates including CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of certain inflammatory diseases. Emricasan is an orally available pan-caspase inhibitor designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. CTS-2090 and CTS-2096 are selective caspase-1 inhibitors targeting inflammasome activation and to treat a variety of inflammation mediated diseases.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +13.75% | 1.5M | |
| -0.37% | 103B | |
| +3.36% | 96.73B | |
| +1.66% | 21.31B | |
| -16.19% | 21.21B | |
| -6.82% | 18.79B | |
| -41.41% | 16.37B | |
| -23.01% | 13.68B | |
| +6.87% | 13.44B | |
| +21.79% | 10.98B |
- Stock Market
- Equities
- HSTO Stock
